These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8492948)

  • 21. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Polyneuropathy and fasciitis in eosinophilia-myalgia syndrome].
    Hetzel W; Dangel P; Molitor H
    Fortschr Neurol Psychiatr; 1991 Oct; 59(10):425-31. PubMed ID: 1662183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements.
    Clauw DJ; Flockhart DA; Mullins W; Katz P; Medsger TA
    J Rheumatol; 1994 Dec; 21(12):2385-7. PubMed ID: 7699648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.
    Allen JA; Peterson A; Sufit R; Hinchcliff ME; Mahoney JM; Wood TA; Miller FW; Whitfield ML; Varga J
    Arthritis Rheum; 2011 Nov; 63(11):3633-9. PubMed ID: 21702023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome.
    Smith SA
    Adv Exp Med Biol; 1996; 398():359-64. PubMed ID: 8906289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eosinophilia-myalgia syndrome: myopathic electrodiagnostic characteristics.
    Tanhehco JL; Wiechers DO; Golbus J; Neely SE
    Muscle Nerve; 1992 May; 15(5):561-7. PubMed ID: 1584247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
    Horwitz RI; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():60-72. PubMed ID: 8895182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropsychological and emotional sequelae of eosinophilia-myalgia syndrome.
    Hartlage LC; Horton AM
    Int J Neurosci; 1993 Oct; 72(3-4):251-5. PubMed ID: 8138379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of the eosinophilia-myalgia syndrome].
    Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
    Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased activity of the alpha 1(I) procollagen promoter in skin fibroblasts from patients with chronic eosinophilia-myalgia syndrome.
    Hitraya EG; Jimenez SA; Ludwicka A; Silver RM; Varga J
    Int J Biochem Cell Biol; 1997 Jan; 29(1):135-41. PubMed ID: 9076948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Two cases of L-tryptophan ingestion induced eosinophilia-myalgia syndrome].
    Mizutani T; Mizutani H; Hashimoto K; Kishida M; Taniguchi H; Okada H; Murata M; Nakamura Y; Shimizu M
    Nihon Hifuka Gakkai Zasshi; 1991 Apr; 101(5):561-6. PubMed ID: 1890752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ["Eosinophilia-myalgia" syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases].
    Castot A; Bidault I; Bournerias I; Carlier P; Efthymiou ML
    Therapie; 1991; 46(5):355-65. PubMed ID: 1754978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head and neck manifestations of eosinophilia-myalgia syndrome.
    Levine B; Lanza DC; Ficco A; Freundlich B
    Ann Otol Rhinol Laryngol; 1995 Feb; 104(2):90-9. PubMed ID: 7857025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome.
    Silver RM; Sutherland SE; Carreira P; Heyes MP
    J Rheumatol; 1992 Jan; 19(1):69-73. PubMed ID: 1532618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The eosinophilia-myalgia syndrome: current concepts and future directions.
    Kaufman LD
    Clin Exp Rheumatol; 1992; 10(1):87-91. PubMed ID: 1551286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome.
    Read CA; Clauw D; Weir C; Da Silva AT; Katz P
    Chest; 1992 May; 101(5):1282-6. PubMed ID: 1582285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eosinophilia-myalgia syndrome: coming to grips with a new illness.
    Kilbourne EM
    Epidemiol Rev; 1992; 14():16-36. PubMed ID: 1289111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eosinophilia-myalgia syndrome: the aftermath.
    Sack KE; Criswell LA
    South Med J; 1992 Sep; 85(9):878-82. PubMed ID: 1523446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.